CGTLive®’s Weekly Rewind – August 23, 2024

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. BMS’s Application for Expanded Liso-Cel Indication in Follicular Lymphoma Validated by EMA

BMS is seeking to expand liso-cel's indication in the European Union to include adult patients with r/r FL who have previously received at least 2 prior lines of systemic therapy.

2. Detecting Translocations in Gene Edited Cells

Vanee Pho, PhD, the chief product officer at Mission Bio, discussed the company’s Genome Editing Solution.

3. ImmPACT Bio’s CD19/CD20 CAR-T IMPT-514 Cleared for Phase 1 Trial in Multiple Sclerosis

The company expects to launch a study during the first half of next year.

4. Achilles Therapeutics Makes Progress in Phase 1/2a Clinical Trials for Neoantigen Reactive T-Cell Therapy in NSCLC and Melanoma

The company noted that the first 3 patients with enhanced host conditioning have been dosed in the CHIRON and THETIS trials evaluating ATL001.

5. Evaluating Engineered Tregs for Potential in Treating Multiple Sclerosis

Travis Drow, BS, a research scientist at Seattle Children's Research Institute, discussed mouse model research he presented at ASGCT’s 2024 Meeting.